Rachel Tompa

1 week ago | medicalxpress.com | Rachel Tompa |Sadie Harley |Andrew Zinin

A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortality across the United States. The findings, titled "Escalating Impact of Alcohol-Related Cancer Mortality in the U.S.: A call for action," were presented at ASCO 2025, the annual meeting of the American Society of Clinical Oncology in Chicago.

Dec 8, 2024 | news.med.miami.edu | Rachel Tompa

By: Rachel Tompa, Ph.D. | December 08, 2024 | 7 min. read |  Share Article SummaryTwo clinical trials led by Sylvester researchers have tested the antibody loncastuximab tesirine in patients with different lymphomas and both show encouraging results.

Nov 22, 2024 | scopeblog.stanford.edu | Jennifer Welsh |Christopher Vaughan |Rachel Tompa

When a 67-year-old man entered the office of Giselle Salmasi, MD, seeking a second opinion about a severe, mysterious blood-clotting condition, she knew she needed to act quickly. "There was an urgency to find answers," said the Stanford Medicine clinical associate professor of hematology. It turned out that the man's condition was new to medicine; it had been pinpointed in others only a year earlier by a doctor at the Mayo Clinic.

Nov 18, 2024 | med.stanford.edu | Rachel Tompa

"This opens a whole new way of thinking about the role of chaperones in brain development," said Frydman, who is one of the senior authors on the study. All the patients the researchers identified have one healthy copy of the TRiC complex gene in addition to the mutated version. That squares with the chaperone's importance - two mutated copies of any of these genes would likely be lethal.

Nov 14, 2024 | medicine.yale.edu | Rachel Tompa

With more than 6 million people in the U.S. suffering from opioid use disorder, methods to treat addiction and its fallout are sorely needed. But the most evidence-based treatment method—medication for opioid use disorder—is significantly underused. A new study led by researchers at Yale School of Medicine (YSM) and published Nov. 13 in the journal JAMA Network Open found that fewer than half of psychiatric hospitals in the U.S. have such medications available for their patients.